Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis.

Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.